» Articles » PMID: 35262576

Clinical, Laboratory, and Imaging Profile in Patients with Systemic Amyloidosis in a Brazilian Cardiology Referral Center

Abstract

Background: Systemic amyloidosis is a disease with heterogeneous clinical manifestations. Diagnosis depends on clinical suspicion combined with specific complementary methods.

Objective: To describe the clinical, laboratory, electrocardiographic, and imaging profile in patients with systemic amyloidosis with cardiac involvement.

Methods: This study was conducted with a convenience sample, analyzing clinical, laboratory, electrocardiographic, echocardiographic, nuclear medicine, and magnetic resonance data. Statistical significance was set at p < 0.05.

Results: A total of 105 patients were evaluated (median age of 66 years), 62 of whom were male. Of all patients, 83 had transthyretin (ATTR) amyloidosis, and 22 had light chain (AL) amyloidosis. With respect to ATTR cases, 68.7% were the hereditary form (ATTRh), and 31.3% were wild type (ATTRw). The most prevalent mutations were Val142Ile (45.6%) and Val50Met (40.3%). Time from onset of symptoms to diagnosis was 0.54 and 2.15 years, in the AL and ATTR forms, respectively (p < 0.001). Cardiac involvement was observed in 77.9% of patients with ATTR and in 90.9% of those with AL. Alterations were observed in atrioventricular and intraventricular conduction in 20% and 27.6% of patients, respectively, with 33.7% in ATTR and 4.5% in AL (p = 0.006). In the ATTRw form, there were more atrial arrhythmias than in ATTRh (61.5% versus 22.8%; p = 0.001). On echocardiogram, median septum thickness in ATTRw, ATTRh, and AL was 15 mm, 12 mm, and 11 mm, respectively (p = 0.193). Elevated BNP was observed in 89.5% of patients (median 249, ICR 597.7), and elevated troponin was observed in 43.2%.

Conclusion: In this setting, it was possible to characterize cardiac involvement in systemic amyloidosis in its different subtypes by means of clinical history and the diagnostic methods described.

Citing Articles

A case series of patients with cardiac amyloidosis evaluated at a Colombian university hospital.

Lopez-Ponce de Leon J, Granados-Alvarez S, Arango-Ibanez J, Montero Echeverri J, Arteaga Tobar A, Garcia A Front Cardiovasc Med. 2025; 12:1487717.

PMID: 39981348 PMC: 11841452. DOI: 10.3389/fcvm.2025.1487717.


Unraveling the Challenges in Diagnosing Cardiac Amyloidosis.

Squassante Capeline L Arq Bras Cardiol. 2024; 121(4):e20240107.

PMID: 38775616 PMC: 11081089. DOI: 10.36660/abc.20240107.


[Cardiac arrhythmias and amyloidosis].

Salinas-Arce J, Alca-Clares R, Gonzales-Luna A, Cabrera-Saldana M, Mendoza-Novoa P, Solorzano-Altamirano P Arch Peru Cardiol Cir Cardiovasc. 2023; 3(2):82-97.

PMID: 37351307 PMC: 10284580. DOI: 10.47487/apcyccv.v3i2.217.


Utility of Biomarkers in Suspected Cardiac Amyloidosis: Opportunity for More Frequent and Early Diagnosis.

Barbosa-Ferreira J, Oliveira A Arq Bras Cardiol. 2022; 119(2):223-224.

PMID: 35946683 PMC: 9363050. DOI: 10.36660/abc.20220437.


Amyloidosis for Cardiologists.

Pedrosa R Arq Bras Cardiol. 2022; 118(2):433-434.

PMID: 35262577 PMC: 8856688. DOI: 10.36660/abc.20210959.

References
1.
Sattianayagam P, Hahn A, Whelan C, Gibbs S, Pinney J, Stangou A . Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2011; 33(9):1120-7. DOI: 10.1093/eurheartj/ehr383. View

2.
Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk R, Ferrari V . ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019; 26(6):2065-2123. DOI: 10.1007/s12350-019-01760-6. View

3.
Syed I, Glockner J, Feng D, Araoz P, Martinez M, Edwards W . Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010; 3(2):155-64. DOI: 10.1016/j.jcmg.2009.09.023. View

4.
Ruberg F, Grogan M, Hanna M, Kelly J, Maurer M . Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019; 73(22):2872-2891. PMC: 6724183. DOI: 10.1016/j.jacc.2019.04.003. View

5.
Quarta C, Solomon S, Uraizee I, Kruger J, Longhi S, Ferlito M . Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 2014; 129(18):1840-9. DOI: 10.1161/CIRCULATIONAHA.113.006242. View